Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Cavia porcellus | Bradykinin B2 receptor | Starlite/ChEMBL | References |
Homo sapiens | bradykinin receptor B2 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | pyroglutamylated rfamide peptide receptor | bradykinin receptor B2 | 391 aa | 354 aa | 19.2 % |
Schistosoma mansoni | biogenic amine (octopamine/dopamine) receptor | Bradykinin B2 receptor | 372 aa | 326 aa | 22.7 % |
Schistosoma japonicum | ko:K04134 cholinergic receptor, invertebrate, putative | Bradykinin B2 receptor | 372 aa | 313 aa | 19.2 % |
Loa Loa (eye worm) | hypothetical protein | Bradykinin B2 receptor | 372 aa | 311 aa | 23.5 % |
Onchocerca volvulus | Mitochondrial inner membrane protein homolog | Bradykinin B2 receptor | 372 aa | 339 aa | 23.9 % |
Brugia malayi | putative neuropeptide receptor NPR1 | Bradykinin B2 receptor | 372 aa | 312 aa | 24.0 % |
Schistosoma mansoni | peptide (allatostatin)-like receptor | Bradykinin B2 receptor | 372 aa | 337 aa | 25.5 % |
Echinococcus granulosus | neuropeptide receptor | Bradykinin B2 receptor | 372 aa | 338 aa | 24.0 % |
Loa Loa (eye worm) | neuropeptide F receptor | Bradykinin B2 receptor | 372 aa | 355 aa | 21.4 % |
Echinococcus multilocularis | neuropeptide receptor | Bradykinin B2 receptor | 372 aa | 305 aa | 24.6 % |
Onchocerca volvulus | Bradykinin B2 receptor | 372 aa | 305 aa | 24.3 % | |
Schistosoma japonicum | ko:K04135 adrenergic receptor, alpha 1a, putative | Bradykinin B2 receptor | 372 aa | 335 aa | 22.7 % |
Schistosoma mansoni | adenoreceptor | Bradykinin B2 receptor | 372 aa | 361 aa | 21.1 % |
Onchocerca volvulus | Bradykinin B2 receptor | 372 aa | 323 aa | 20.7 % | |
Schistosoma japonicum | Rhodopsin, putative | Bradykinin B2 receptor | 372 aa | 323 aa | 20.4 % |
Onchocerca volvulus | Bradykinin B2 receptor | 372 aa | 383 aa | 20.9 % |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 8.9 nM | Concentration required to inhibit specific binding of [3H]-BK at 0.06 nM to Bradykinin receptor B2 in guinea pig ileum membrane preparations by 50%. | ChEMBL. | 9767642 |
IC50 (binding) | = 8.9 nM | Concentration required to inhibit specific binding of [3H]-BK at 0.06 nM to Bradykinin receptor B2 in guinea pig ileum membrane preparations by 50%. | ChEMBL. | 9767642 |
IC50 (binding) | = 480 nM | Concentration required to inhibit specific binding of [3H]-BK at 1.2 nM to A-431 cells (human epidermoidcarcinoma) which express Bradykinin receptor B2 by 50%. | ChEMBL. | 9767642 |
IC50 (binding) | = 480 nM | Concentration required to inhibit specific binding of [3H]-BK at 1.2 nM to A-431 cells (human epidermoidcarcinoma) which express Bradykinin receptor B2 by 50%. | ChEMBL. | 9767642 |
Inhibition (functional) | 0 % | Compound tested in vivo for inhibition of Bradykinin induced Bronchoconstriction in anaesthetized guinea pig.(P<0.01); % Inhibition at 1 mg/kg. p.o.; NT= Not Tested | ChEMBL. | 9767642 |
Inhibition (functional) | 0 % | Compound tested in vivo for inhibition of Bradykinin induced Bronchoconstriction in anaesthetized guinea pig; % Inhibition at 3.2 mg/Kg p.o.; NT= Not Tested | ChEMBL. | 9767642 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.